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Abstract
Background: HIV-1 genotypic drug resistance is an important threat to the success of antiretroviral therapy and transmitted
resistance has reached 9% prevalence in Europe. Studies have demonstrated that HIV-1 DNA load in peripheral blood
mononuclear cells (PBMC) have a predictive value for disease progression, independently of CD4 counts and plasma viral
load.
Methodology/Principal Findings: Molecular-beacon-basedreal-time PCR wasusedto measureHIV-1 secondtemplate switch
(STS) DNA in PBMC in newly-diagnosed HIV-1 patients across Europe. These patients were representative for the HIV-1
epidemic in the participating countries and were carrying either drug-resistant or sensitive viral strains. The assay design was
improved from a previous version to specifically detect M-group HIV-1 and human CCR5 alleles. The findings resulted in a
median of 3.32 log10 HIV-1 copies/10
6 PBMC and demonstrated for the first time no correlation between cellular HIV-1 DNA
load and transmitted drug-resistance. A weak association between cellular HIV-1 DNA levels with plasma viral RNA load and
CD4
+ T-cell counts was also reconfirmed. Co-receptor tropism for 91% of samples, whether or not they conferred resistance,
was CCR5. A comparison of pol sequences derived from RNA and DNA, resulted in a high similarity between the two.
Conclusions/Significance: An improved molecular-beacon-based real-time PCR assay is reported for the measurement of
HIV-1 DNA in PBMC and has investigated the association between cellular HIV-1 DNA levels and transmitted resistance to
antiretroviral therapy in newly-diagnosed patients from across Europe. The findings show no correlation between these two
parameters, suggesting that transmitted resistance does not impact disease progression in HIV-1 infected individuals. The
CCR5 co-receptor tropism predominance implies that both resistant and non-resistant strains behave similarly in early
infection. Furthermore, a correlation found between RNA- and DNA-derived sequences in the pol region suggests that
genotypic drug-resistance testing could be carried out on either template.
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Introduction
The development of antiretroviral therapy to fight HIV-1
infection has lead to a significant decrease in mortality and
morbidity among infected populations. Nevertheless, the emer-
gence of viral species resistant to drugs presents a major problem
in the desired response to therapy. In the past decade, studies have
been focusing on the transmission of such species in different parts
of the world and it has been estimated that transmitted drug
resistance occurs in about 9% of all newly diagnosed HIV-1
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e10976patients across Europe, USA and Canada [1,2,3,4,5,6]. Also,
transmitted resistance cases are frequently found to be clustered
[7,8]. This is probably explained by transmitted cases introduced
before HAART became available, continuing to be transmitted
today.
Integrated HIV-1 DNA in host genomic DNA acts as a latent
reservoir and ensures viral persistence in spite of prolonged
antiretroviral therapy [9,10,11,12,13,14,15]. This persistent cellu-
lar reservoir can reactivate itself and replenish viral infection,
presenting itself as one of the current challenges for the control of
HIV-1 infection progression [16,17,18]. Cellular HIV-1 DNA
load is a marker associated with the viral reservoir and with
the spread of the virus. Studies in patients with primary HIV-1
infection and advanced HIV-1 disease have demonstrated
that early levels of HIV-1 DNA load in peripheral blood
mononuclear cells (PBMC) and in CD4
+ T-cells have a predictive
value for long-term virological outcome and for disease progres-
sion, independently of CD4 counts and plasma viral RNA load
[19,20,21,22,23,24,25,26,27,28,29,30,31,32]. Many in-house pro-
tocols have been developed for the quantification of cellular HIV-1
DNA in its different forms, including end-point and real-time PCR
assays [33]. However, there is still no universal or standardised
way to monitor and report HIV-1 DNA quantities.
Here we present an improved method of quantification of
cellular HIV-1 DNA levels. We measure the concentration of
HIV-1 DNA forms which have undergone the second template
switch (STS DNA) in PBMC. This detects a pool of HIV-1 forms
that includes integrated and unintegrated linear dsDNA viral
genomes and 1- and 2-LTR circles. A cohort of newly-diagnosed
patients was studied for genotypic drug resistance, co-receptor
tropism and cellular viral DNA load.
Methods
Ethics statement
The present study was performed as part of the EuropeHIV-
Resistance network (www.europehivresistance.org), and ethical
requirements were fulfilled according to the procedure described
in the European Commission contract for EHR (project LHSP-
CT-2006-518211). The procedure differs among the ten countries
in the network according to national legislation. Briefly, for each
participating hospital or collection centre, approval was obtained
by the institutional or national medical ethical review committee
and a written informed consent was obtained for each patient. In
countries where a mandatory surveillance system was already
established, legally no informed consent was needed. All samples
were analysed anonymously and coded at national level. The
names of the institutional review boards and committees are: the
‘‘Commissie voor Medische Ethiek van de faculteit Geneeskunde’’
associated with University Hospital Gasthuisberg, Leuven, Bel-
gium; the ‘‘Dr. Fran Mihaljevic’’ University Hospital for Infectious
Diseases Ethics Committee, Zagreb, Croatia; the Cyprus National
Bioethics Committee, Nicosia, Cyprus; the ‘‘Videnskabsetiske
Komite for VejleFyns Amter’’ and ‘‘Datatilsynet’’, Copenhagen,
Denmark; the Bioethical Committee of the Medical School,
National and Kapodistrian University of Athens, Greece; the
Helsinki Committee for Bioethics for Israel; the Ethics Committee
for Clinical Trials, ’L. Sacco’ Hospital, Milan, Italy; the ‘‘Comite
National D’Ethique a la Recherche (CNER)’’, Luxemburg; the
Medical Ethics Committee at the Ministry of Health of Slovenia;
and ‘‘Comite ´E ´tico de Investigacio ´n Clı ´nica, Hospital Universitari
Germans Trias i Pujol’’, Barcelona, Spain. Approval was not
required from an institutional review board for Greece as samples
were made anonymous and coded on a national level.
Sample and data collection
Included in this study were samples from 253 newly-diagnosed
HIV-1 seropositive individuals from ten countries-members of the
EuropeHIVResistance network: Belgium, Croatia, Cyprus, Den-
mark, Greece, Israel, Italy, Luxemburg, Slovenia and Spain.
Sample data were obtained from the database of the E. C.-funded
project EuropeHIVResistance [1], which studies the epidemiology
of drug resistance among patients newly diagnosed with HIV-1
across Europe [6]. Patients were representative for the risk group
and geographical distribution of the national HIV epidemic and
were included within six months after diagnosis.
PBMC isolation and genomic DNA extraction
PBMC were isolated from blood samples by one of two
methods. Samples from 120 individuals were isolated from blood
collected in BD VacutainerH CPTTM (BD, Franklin Lakes, NJ,
USA) tubes according to manufacturer’s instructions. Samples
from 71 individuals were extracted from blood collected in EDTA
tubes by Ficoll density gradient centrifugation (Lymphoprep;
Nycomed, Oslo, Norway). CPT
TM and Ficoll density gradient
separation have been found to perform equivalently in maintain-
ing the quality and function of PBMC from HIV seropositive
blood samples [34]. Genomic DNA was extracted from the
isolated PBMC using the QIAmp DNA Blood Mini kit (Qiagen,
Valencia, CA, USA) and eluted with 100 ml AE buffer following
the manufacturer’s instructions. DNA quality and quantity was
evaluated for all samples by UV spectrophotometry using
NanoDrop ND-1000 (NanoDrop Technologies, Wilmington,
DE, USA).
Genomic DNA extraction from whole blood
DNA from samples from 62 individuals was extracted from
whole blood collected in EDTA tubes. For 15 samples, DNA was
isolated from 0.5 ml whole blood using the QIAmp DNA Blood
Mini kit (Qiagen) and eluted in 100 ml AE buffer. For 47 samples,
DNA was isolated from 0.3 ml whole blood using the High Pure
PCR Template Preparation kit (Roche Molecular Diagnostics,
Manheim, Germany), and eluted in 50 mld H 2O. Due to the
production of irregular signals from the real-time PCR, the latter
samples were cleaned using the cleaning and elution steps of the
QIAmp DNA Blood Mini kit (Qiagen), and eluted in 100 mlA E
buffer.
HIV-1 subtyping and determination of drug-resistance
Samples were amplified and sequenced in the pol region as
described previously [35]. Subtype was determined by uploading
the sequences individually into the REGA HIV-1 & 2 Automated
Subtyping Tool v2.0 [36]. This was confirmed with phylogenetic
analysis by constructing a Neighbour-Joining tree [37] using the
Kimura-2-parameter distance estimation approach [38] with
MEGA v4 [39]. The reliability of clustering was evaluated using
bootstrap analysis with 1,000 replicates [40], where bootstrap
values above 70 were considered significant for subtype assign-
ment. Standard reference sequences used in the REGA HIV
subtyping tool [36] were downloaded from the website (http://
www.bioafrica.net/rega-genotype/html/subtypinghiv.html).
Drug resistance in the samples was determined by examination
of the PR/RT sequence of each for mutations known to confer
resistance to protease and reverse transcriptase inhibitors. This
was done by manually examining the sequences and verified
automatically using the Stanford drug-resistance algorithm
[41,42], as described previously [35]. TDRM have been defined
as the presence of at least one of the following mutations in
Cellular HIV-1 DNA Load
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90M; or RT: 41L, 44D, 62V, 65R, 67N, 69D/insert, 70R, 74V,
75I, 77L, 100I, 103N, 106A/M, 108I, 115F, 116Y, 151M, 181C/
I, 184I/V, 188C/H/L, 190A/S, 210W, 215Y/F, 215 revertants
A/C/D/E/G/H/I/L/N/S/V, 219Q/E, 225H, 230L, 236L [43].
Comparison of RNA- and DNA-associated pol sequences
HIV-1 pol nucleotide sequences covering the PR/RT region
derived from plasma viral RNA and cellular DNA were compared
to determine any correlation between the two. The sequences
were examined in the positions known to confer resistance to
antiretroviral drugs, in order to establish whether the genotypic
drug resistance testing on the two types of sequences resulted in
different data.
Determination of co-receptor tropism by HIV-1 V3-loop
amplification and sequencing
All samples were amplified by PCR in the V3-loop region with a
nested PCR using extracted genomic DNA from the PBMC
samples. The primary PCR was performed using 3 ml DNA in a
50 ml reaction using PlatinumH PCR SuperMix (Invitrogen,
Carlsbad, CA, USA) with 20 pmol each of the outer forward (59-
ATGGGATCAAAGCCTAAAGCCATGTG-39, positions 6557-
6582) and reverse (59- AGTGCTTCCTGCTGCTCCCAAGAA-
CCCAAG-39, positions 7811-7782) primers. The cycling conditions
were one cycle at 94uC for 2 min, 40 cycles at 94uC for 20 s, 55uC
for 30 s, 72uC for 30 s, and a final step at 72uCf o r7m i n .An e s t e d
PCR was performed using 3 ml of the primary PCR product with 20
pmol each of the inner forward (59-CCAATTCCCATACAT-
TATTGTGCCC-39, positions 6858-6882) and reverse (59-TTAC-
AGTAGAAAAATTCCCCTCCACAATTAAA-39, positions 7381-
7350) primers in a 50 ml reaction, with the same cycling conditions as
above, but with an annealing temperature of 52uC. Cycle sequencing
PCR was performed on purified amplicons bidirectionally using the
inner forward and reverse amplification primers by means of the
BigDyeH Terminator system v3.1 (Applied Biosystems, Foster City,
CA, USA). The products were sequenced directly on the ABI 3300
Genetic Analyser (Applied Biosystems). The resulting readings were
analyzed with the Sequencing Analysis Software v5.2 (Applied
Biosystems). To determine the co-receptor tropism of the samples,
sequences were uploaded into the geno2pheno [44] and WebPSSM
[45,46] automated bioinformatics tools, using default settings.
Cellular HIV-1 STS load in newly-diagnosed, drug-naı ¨ve
samples
To uniquely detect HIV-1 DNA structures that have completed
the two template switches, a molecular-beacon-based real-time
PCR assay reported previously [20] has been improved for better
compatibility and specificity to the target, by using the general
method of quantifying single sequences with nucleotide-specific
molecular beacons [47] and real-time PCR [48] as previously
described [20,49]. The assay uses primers that amplify a smaller
region, from the end of U5 to just before the gag sequence, from
position 623 to 788 (numbers according to sequence HXB2). The
PCR primers and the target recognition sequence of the molecular
beacon were designed to hybridize on conserved regions from all
the genetic subtypes within the M group based on a comprehen-
sive DNA sequence alignment from published HIV-1 sequences
(Table 1 and Figure 1). This assay detects only HIV-1 DNA
structures that have undergone both single stranded DNA
template switches, including both unintegrated and integrated
linear viral genomes. To confirm the specificity of the design,
amplicons were sequenced and found to contain the correct
region. To assess the thermodynamic characteristics, the quality
and the purity of the molecular beacon, a melting curve analysis
was performed by monitoring the fluorescence thermal transition
profiles using the 7900HT Real-Time PCR System (Applied
Biosystems, Foster City, California, USA). The cycling parameters
were as follows: 1 cycle for 2 min at 95uC followed by 50 cycles
each consisting of the data collection step for 30 s and a second
step for 10 s, starting at 80uC with an auto-incrementation of
21uC per half-minute cycle until 31uC were reached. The
reaction consisted of a 25 ml mixture containing 1X PlatinumH
Quantitative PCR Supermix-UDG (Invitrogen, Carlsbad, CA),
5.7 pmol of the beacon probe with or without 100 pmol of a
perfectly complementary single-stranded oligonucleotide target.
Changes in fluorescence were measured at 490 nm and the data
collected at each temperature interval were plotted to form these
thermal denaturation profiles and determine the optimal anneal-
ing temperature for the real-time PCR reaction.
Table 1. Molecular beacons and primers used in the real-time PCR assay.
Name Oligonucleotide Sequence (59-39)
a Position
b Reference
HIV-1
MB684 Molecular beacon FAM-CCGCTGCAAGCCGAGTCCTGCGTCGAGACAGCGG-Dabcyl 684–705 Modified from [20]
623 Forward primer AAATCTCTAGCAGTGGCGCCCGAA 623–646 Modified from [20]
788 Reverse primer TCTCTCCTTCTAGCCTCCGCTAGT 765–788 Modified from [20]
CCR5
LK155 Molecular beacon TET-GCGCCTATGACAAGCAGCGGCAGGAGGCGC-Dabcyl 623–641 Kostrikis et al., unpublished
data
LK46 Forward primer GCTGTGTTTGCGTCTCTCCCAGGA 478–501 Kostrikis et al., unpublished
data
LK47.new Reverse primer CACAGCCCTGTGCCTCTTCTTCTCA 690–713 Kostrikis et al., unpublished
data
aFAM, fluorescein; TET, Tetrachloro-69-carbofluorescein; Dabcyl, 4-(49-dimethylamino phenylazo)benzoic acid; underlined sequences indicate the complementary
sequences forming the molecular beacon hairpin structures.
bPositions correspond to the GenBank sequences K03455 and U83326.1 for HIV-1 and CCR5, respectively. For molecular beacons, the nucleotide positions correspond to
the target recognition sequences (non-underlined sequences).
doi:10.1371/journal.pone.0010976.t001
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PLoS ONE | www.plosone.org 3 June 2010 | Volume 5 | Issue 6 | e10976Figure 1. Schematic diagram of the HIV-1 assay design. Schematic diagram of the HIV-1 genome (A) and the region targeted in this study (B).
Below (C), a sequence alignment of the HXB2 strain and consensus sequences of the most widely distributed subtypes in the M group from
nucleotide position 600 to 800 according to the numbering of strain HXB2, constructed from sequences available on the Los Alamos HIV sequence
database (labelled as CONS). For each of the subtypes H, CRF03_AB and CRF08_BC only one sequence was available in this region and a consensus
could not be made (labelled as STRAIN). No sequences were available for subtypes J and K in this region. The sequences and names of the primers
and molecular beacon used in this study are seen in bold above the alignment. Directly below the beacon and reverse primer sequence is the
complementary sequence corresponding to the viral positive strand. Above the beacon sequence is a schematic representation of the beacon in its
closed conformation (hairpin loop). The beacon probe is labelled with a fluorophore (FAM) on the 59end (seen as a green circle) and a DABCYL
quencher on the 39end (seen as a dark grey circle). The primer and molecular beacon sequences and their exact targets in the alignments are
highlighted in grey. Dots in the sequences represent unseen regions of the alignment and dashes represent gaps in the sequences produced by the
alignment.
doi:10.1371/journal.pone.0010976.g001
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To quantify the number of cells in the input DNA, a molecular-
beacon-based real-time PCR assay was used for the detection of
CCR5 alleles. The design was based on a previously published
protocol [20] and is an improved version for the quantification of a
region of the human CCR5 gene adjacent to the D32 deletion,
which exists at two copies per cell (L. G. Kostrikis, unpublished
data), allowing the quantification of genomic equivalents in a given
sample. The PCR primers and the target recognition sequence of
the molecular beacon are listed in Table 1. A thermal
denaturation curve was constructed as described above, with 6.5
pmol of the CCR5-specific molecular beacon.
CCR5 and HIV-1 standards and standard curves
Cloned plasmids containing within them the targeted HIV-1
DNA and CCR5 amplicons of the real-time PCR assays were used
as external quantification standards in the experiments. The
amplicons were cloned into plasmids (TOPO TA CloningH Kit,
pCR 4-TOPO vector, Invitrogen, Carlsbad, CA, USA) following
PCR with the primers seen in Table 1. Five clones of each were
selected and sequenced on the ABI 3130 Genetic Analyzer
(Applied Biosystems, Foster City, CA, USA) using the vector
primers available from the cloning kit (Invitrogen) as sequencing
primers, to ensure correct insertion of the amplicons into the
plasmids. Concentrations were measured by UV absorbance using
a NanoDrop 1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE, USA) and the copy number per unit volume was
calculated. Tenfold serial dilutions of the purified plasmids of
known molar concentrations were used as templates to generate
standard curves in the selective amplification assays. Standard
curves were made by plotting the threshold cycle of known CCR5
and HIV-1 copies per reaction. The slope and correlation
coefficient of each standard curve were calculated based on the
median threshold cycle (CT) values measured for replicates of each
dilution point ranging from 10
6 to 10
1 DNA templates. The PCR
efficiency, E, corresponding to the experimentally derived
dynamic range was computed as (10
21/s 2 1)6100, where s is
the slope of the standard curve generated.
For the real-time PCR reaction, each 25 ml reaction mixture
contained 5 ml of extracted genomic DNA, 20 pmol each of
forward and reverse primer, 1X PlatinumH qPCR Supermix-
UDG (Invitrogen, Carlsbad, CA, USA). For the CCR5 reaction,
6.5 pmol of beacon LK155 were used and in the HIV-1 reaction,
5.7 pmol of beacon MB684. The cycling conditions were the same
for the two reactions and are as follows: one cycle of denaturation
(95uC for 10 min), followed by 50 cycles of amplification
(denaturation at 95uC for 15 s, annealing and data collection at
55uC for 30 s, and polymerization at 72uC for 30 s), performed on
the 7900HT Real-Time PCR System (Applied Biosystems, Foster
City, CA, USA). During the data-collection stage of each cycle,
fluorescence emission was recorded at 490 nm.
Quantification of cellular HIV-1 STS DNA in newly-
diagnosed, drug-naı ¨ve samples
Two uniplex molecular beacon-based real-time assays were
carried out in triplicate for absolute quantification of CCR5 copies
and HIV-1 STS DNA copies in clinical samples, as described
above for the standards. In each experiment, standard curves for
HIV-1 and human CCR5 templates were also run in triplicate by
using six serial dilutions, ranging from 10
6 to 10
1 copies, along
with no-template negative controls. Each experiment was assessed
by the quality of its standard curves, i.e. slope, R
2-value and y-
intercept. CCR5 and HIV-1 copies in each sample were
quantified by use of the obtained threshold values from the
samples and the corresponding standard curve, constructed from
multiple measurements of standards. In each sample, the number
of cells was quantified as one cell per two CCR5 copies, and the
HIV-1 STS DNA levels were calculated per 10
6 PBMC. The
cellular viral load of a sample is, therefore, the number of HIV-1
copies per million cells.
For samples whose DNA was extracted from whole blood, HIV-
1 STS DNA was quantified per ml blood and CCR5
measurements were not made, as whole blood contains many cell
types, and not only PBMC. Hence, HIV-1 STS DNA load in
samples obtained from whole blood are not comparable to samples
extracted from PBMC.
Statistical analysis
Viral loads were log-transformed. The cellular viral load was
compared between patients infected with or without a drug
resistant virus using the Mann-Whitney test. Categorical variables
were compared using chi-square test. To determine whether a
differential cellular viral load was observed between subtypes a
Kruskal-Wallis test was performed. The 95% confidence interval
of the prevalence of transmitted resistance was calculated using the
Wilson score interval. The association between the plasma viral
load and the cellular viral load was determined using Pearson’s
correlation coefficient.
Results
Description of the population
Available were 191 PBMC samples from HIV-1 infected
individuals from eight country-members of the EuropeHIVResis-
tance network. A total of 30 samples were excluded from the
analysis due to failure of PCR in the pol region (n=18), or a
polymorphic nature of the sequence (n=12), and drug-resistance
could therefore not be determined. Table 2 lists the baseline
characteristics of the 161 study subjects that were included in the
analysis. The median age of the participants was 34 (interquartile
range IQR 29–42) and they were predominantly male (72.0%), a
fact also reflected by a large proportion of MSM (50.3%). The
median log10 plasma RNA load in the samples studies was 4.43
copies per ml (IQR 3.87–5.14) and the median CD4
+ T-cell count
was 423 per ml (IQR 255.3–578.5).
HIV-1 subtyping,drug-resistance and co-receptor tropism
HIV-1 subtype was determined using the pol sequences obtained
above using REGA [36] and by phylogenetic analysis. The results
are listed in Table 2 and the phylogenetic tree is seen in Figure 2.
The most frequently observed subtype was B (64%), followed by A
(14.3%) and C (8.7%). Interestingly, cases of complex recombi-
nants (C/H/K, CRF2/B) were also present in the dataset.
Sequences of all samples were examined for known resistance
mutations to available protease and reverse transcriptase inhibi-
tors. Transmitted resistance in the form of major drug resistant
mutations was observed in 11.7% (95% confidence interval 7.6 to
17.6%) of the samples.
All samples were sequenced in the V3-loop and tropism was
determined by the geno2pheno and WebPSSM automated
bioinformatics tools. The majority of samples were CCR5-tropic
(147 samples, 91.3%), and the rest were CXCR4-tropic (5
samples, 3.1%) or a mixture of CCR5 and CXCR4 (7 samples,
4.3%). Two samples (1.2%) could not be determined due to the
polymorphic nature of the V3-loop sequence. None of the five
CXCR4-tropic samples displayed genotypic drug-resistance, but
Cellular HIV-1 DNA Load
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resistant samples were purely CCR5-tropic.
Comparison of RNA- and DNA-associated pol sequences
Known positions conferring resistance to antiretroviral therapy
from HIV-1 pol nucleotide sequences covering the PR/RT region
derived from plasma viral RNA and cellular DNA were compared
for each sample, to determine any correlation between the two.
The comparison showed that there is a high similarity between the
two types of sequences.
Characteristics of the real-time PCR assay for
quantification of HIV-1 STS DNA in PBMC
Thermal denaturation profiles of both molecular beacons were
constructed as described in Materials and Methods and are seen in
Figure 3. The optimum concentrations of the molecular beacons
were determined, as was the optimum temperature for annealing
and data collection in the PCR reactions (55uC). The HIV-1 STS
DNA and CCR5 assays’ specificity was established by accurate
detection of 10 DNA copies with a 6-log10 linear dynamic range.
The slopes of the standard curves (Figure 3) were -3.3 cycles/log10
DNA templates for both assays, corresponding to PCR efficiencies
of .99%. The capability of the STS DNA assay to detect HIV-1
strains within the M group was evaluated by using DNA extracted
from primary PBMC samples isolated from patients infected with
HIV-1 strains from genetic subtypes A, B, C, D, F1 and G and
recombinant strains A/G, C/H/K, CRF01_AE, CRF02_AG and
CRF02/B. The specificity of the STS DNA assay against human
genomic DNA were examined using DNA extracted from
individuals not infected with HIV-1; the results were negative,
with no detection after 50 PCR cycles (data not shown).
Cellular HIV-1 STS load in newly-diagnosed drug-naı ¨ve
samples
The DNA samples extracted from whole blood produced very
low proportion of detectable HIV-1 DNA levels (data not shown),
due to the fact that whole blood contains many cell types, and
were not used in the analysis. The values of cellular HIV-1 STS
DNA loads in 191 samples extracted from PBMC of newly-
diagnosed individuals from eight European countries were
measured using molecular beacon-based real-time PCR assays
quantifying HIV-1 STS DNA and human CCR5 copies per
sample. The cellular HIV-1 STS DNA load was calculated as
HIV-1 STS DNA copies per million cells and the median log10
value measured was 3.32 (IQR 2.92–3.75 log10 copies/10
6 PBMC)
(Figure 4A). These values were investigated according to the
various known parameters of the samples.
The relationship between the cellular HIV-1 DNA loads
measured in this study and other clinical parameters and
characteristics of the samples at the time of sampling were also
investigated. The results show that the cellular HIV-1 STS levels
have a weak correlation with the corresponding plasma RNA
Table 2. Characteristics of study subjects.
Characteristics
a Subjects N=161 (%)
Sampling country
Belgium 18 (11.2)
Croatia 5 (3.1)
Cyprus 40 (24.8)
Greece 8 (5.0)
Israel 18 (11.2)
Luxembourg 42 (26.1)
Slovenia 21 (13.0)
Spain 9 (5.6)
Year of sampling
2002 6 (3.7)
2003 31 (19.3)
2004 12 (7.5)
2005 38 (23.6)
2006 27 (16.8)
2007 17 (10.6)
2008 30 (18.6)
Resistance characteristics
Resistant to PI 4 (2.5)
Resistant to RTI 15 (9.3)
No resistance 142 (88.2)
Gender
Male 116 (72.0)
Female 28 (17.4)
Unknown 17 (10.6)
Risk group
MSM 81 (50.3)
Heterosexual 43 (26.7)
IVDU 4 (0.2)
Unknown 33 (18.2)
Age (median, IQR)
b 34 (29–41.5)
Log10 cellular HIV-1 DNA load
(median, IQR)
3.32 (2.92–3.75)
Log10 plasma RNA load
(median, IQR)
4.43 (3.87–5.14)
CD4
+ count (median, IQR) 423 (255.3–578.5)
Subtype
A 23 (14.3)
B 103 (64.0)
C 14 (8.7)
D 1 (0.6)
F1 1 (0.6)
G 7 (4.3)
CRF02_AG 6 (3.7)
CRF01_AE 4 (2.5)
C/H/K 1 (0.6)
CRF02_B 1 (0.6)
Tropism
CCR5 147 (91.3)
CXCR4 5 (3.1)
Characteristics
a Subjects N=161 (%)
CXCR4/CCR5 7 (4.3)
N/A 2 (1.2)
aIQR, interquartile range.
bData available for 130 patients.
doi:10.1371/journal.pone.0010976.t002
Table 2. Cont.
Cellular HIV-1 DNA Load
PLoS ONE | www.plosone.org 6 June 2010 | Volume 5 | Issue 6 | e10976levels (Pearson correlation coefficient R
2=0.20; P=0.001) and a
very weak correlation with CD4
+ T-cell counts (Pearson
correlation coefficient R
2=0.04; P=0.013) (Figure 4B and C),
confirming previously acquired data [20]. For statistical reasons,
the analysis regarding subtypes was limited to the three most
frequently observed subtypes, A, B and C. The median cellular
HIV-1 DNA load was different in the three groups (2.91, 3.26 and
3.56 log10 copies/10
6 PBMC respectively), but this difference did
not reach statistical significance (P=0.40).
Figure 5 shows the comparison of the cellular HIV-1 DNA
loads for patients infected with drug-resistant or non-resistant
strains of the virus. The results indicate a trend towards a higher
cellular HIV-1 DNA load in patients with transmitted drug-
resistant strains of the virus (3.64 log10 copies/10
6 PBMC, IQR
2.63–4.25) than in patients infected with wild-type strains (3.27
log10 copies/10
6 PBMC, IQR 2.90–3.73). This difference did,
however, not reach statistical significance (P=0.14). The possibil-
ity of higher cellular viral loads being explained by more recent
infections in the resistance group was investigated but the
proportions of recent infections in patients with or without
evidence of transmitted resistant strains was (3/22) 13.6% and
(10/66) 15.2% respectively (P=1.00), meaning this was not the
case.
Discussion
In this study the association between cellular HIV-1 DNA load
and transmitted drug resistance was examined for the first time,
using an improved molecular beacon-based real-time PCR assay
for quantification of HIV-1 STS DNA and human CCR5 alleles.
The median cellular HIV-1 STS DNA load calculated in this
study is 3.32 log10 copies per 10
6 PBMC. The results of this study
Figure 2. Phylogenetic tree of the samples used in the study. Neighbour-joining phylogenetic tree for the 161 HIV-1 pol sequences (1233
nucleotides, corresponding to positions 2253–3485 of HXB2). Trees were constructed using 48 representative reference sequences from 9 known
subtypes (A through F) and 13 known recombinant strains. The sequences determined in the study are colour-coded, with colours corresponding to
the country of sampling: Belgium (light blue), Croatia (dark blue), Cyprus (yellow), Greece (green), Israel (red), Luxemburg (grey), Slovenia (purple),
Spain (pink). The divergence between any two sequences is obtained by summing the branch length, using the scale at the lower left of each tree.
The numbers indicated at the subtype-determining nodes are percentage bootstrap support for 1,000 replicates.
doi:10.1371/journal.pone.0010976.g002
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DNA load in patients with transmitted drug-resistant strains of the
virus compared to that of patients infected with wild-type strains.
The cellular viral DNA levels found here are higher than those
quantified with the previous version of the assay [20] (P,0.001)
due to the improvement of the specificity of the CCR5
components. This study includes a significant number of patients
from Israel and countries distributed throughout Europe. The
criteria of inclusion, the well-defined datasets and the consistent
sampling method are encouraging parameters supporting the
strength of this report. The results found are comparable to those
found in previous studies of cellular HIV-1 DNA quantification in
treatment-naı ¨ve patients where levels of 2.85–3.2 log10 copies/10
6
PBMC were reported [19,21,29,50,51]. The findings of this study
also indicate a weak association between the cellular HIV-1 DNA
counts and viral RNA levels or CD4
+ T-cell counts, in agreement
with previous findings [20,50,52]. The three main subtypes also
appeared not to have an impact on cellular viral DNA load.
Positions known to confer resistance to antiretroviral drugs in
plasma RNA- and cellular DNA-derived nucleotide sequences
covering the PR/RT region were compared for each patient in
order to asses the level of similarity between them. Significantly, a
high similarity was found between the two, suggesting that
genotypic drug-resistance testing could be carried out on either
starting material.
The co-receptor tropism of all samples was determined from the
cellular DNA and itwas found that 91%of the samples were CCR5-
tropic, as expected for early infections, 3% were CXCR4-tropic and
4% were a mixture of the two types. Hence, it appears that, the
existence of transmitted drug resistance mutations does not affect the
co-receptor tropism of the virus. This data suggests that resistant and
susceptible viral species behave similarly in early infection.
Figure 3. Thermal denaturation curves of the molecular beacons and standard curves for quantification. On the left are normalised
fluorescence thermal transitions of molecular beacon (pink circles) and beacon-target complexes (blue squares) designed for the detection of the
human CCR5 gene and HIV-1 STS DNA. Fluorescence signals differ between the complementary molecular-beacon-target hybrids and the non-
hybridized molecular beacon at temperatures below 60uC. At higher temperatures, secondary structures within and between oligonucleotides are
denatured and the beacon is free in solution in a dynamic open conformation. The temperature selected (55uC) for hybridisation in the standard PCR
reactions allows optimal resolution of the fluorescence signal. On the right are standard curves for human CCR5 and HIV-1 STS DNA templates used in
the real-time PCR assays for quantifying HIV-1 STS DNA in human PBMC. Six serial dilutions ranging from 10
6 to 10
1 DNA templates were made for
each DNA standard, and all standard dilutions were measured by real-time PCR using nucleotide sequence-specific molecular beacons. Median CT
values (6 standard deviations) were measured for a number of replicates for each dilution point, indicated on the standard curves. The correlation
coefficients (R
2) of the standard curves were .0.99, and the PCR efficiencies were .99%.
doi:10.1371/journal.pone.0010976.g003
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reversion of viral strains to wild-type in those samples considered
non-resistant, as this may play a role on cellular viral DNA load as
minority species in the viral population. Nonetheless, reversion
only appears to occur to a limited extent [53]. Another factor that
may influence such findings is the fact that known mutations that
confer resistance to antiretroviral drugs are heterogeneous and
may have differential impact of resistance. The study of different
TDRM individually, however, is not possible with the datasets
currently available. Also, mutations associated with reduced viral
fitness, and therefore lower viral loads, are not found frequently in
transmitted resistant strains due to the fact that the level of plasma
viral load is a key factor in the transmission of the virus [54].
Another point is the possibility of the inclusion of patients who are
in the acute phase of infection at the time of sampling, who may
account for values on the high end of the range of HIV cellular
DNA levels obtained in this study.
The results show for the first time that there is no association
between cellular viral DNA levels and the existence of transmitted
drug resistant mutations in newly-diagnosed patients. Cellular
HIV-1 DNA load has been shown to be associated with disease
progression [19,20,21,23,24,26,29,30,32] and transmitted drug
resistance does not currently have an impact on the time of
treatment initiation. From this data, it is implied that transmitted
drug resistance is not associated with disease progression.
Overall, this report presents an improved methodology of
cellular HIV-1 DNA quantification with molecular beacon-based
real-time PCR. The patients included in the study were newly-
diagnosed individuals from Israel and all over Europe. The data
show a similar co-receptor tropism for resistant and non-resistant
viral species, implying that both behave in a similar manner in
early infection. Significantly, a high correlation was found between
RNA- and DNA-associated PR/RT sequencing indicating that
genotypic drug resistance testing could be carried out on either
type of sample. It was found that no correlation exists between
cellular HIV-1 DNA levels and transmitted drug resistance,
indicating that the latter may not be associated with disease
progression and should continue not having an impact on the time
to initiate treatment in patients.
Figure 4. Cellular HIV-1 STS DNA load against plasma HIV-1
RNA load and CD4
+ T-cell count. Distribution of cellular HIV-1 STS
DNA load (A), plasma HIV-1 RNA load (B) and CD4
+ T-cell counts (C)
among 161, 109 and 161 newly-diagnosed individuals, respectively. The
results indicate a weak correlation between STS DNA levels and plasma
RNA levels (R
2=0.20; P=0.001) and a very weak correlation between
STS DNA levels and CD4
+ counts (R
2=0.04; P,0.001).
doi:10.1371/journal.pone.0010976.g004
Figure 5. Cellular HIV-1 DNA load in drug-resistant and non-
resistant samples. Dot plot of log10 cellular HIV-1 STS DNA load per
million PBMC among 161 newly-diagnosed individuals with major drug-
resistant mutations (n=19) and with no major drug-resistant mutations
(n=142). The results indicate a trend towards higher cellular HIV-1 STS
DNA load (P=0.14) in resistant samples (median 3.64, IQR 2.63–4.25)
compared to non-resistant samples (median 3.27, IQR 2.90–3.73).
doi:10.1371/journal.pone.0010976.g005
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